In the trial, 14 adult patients with stable T2DM and biopsy-proven MASH (metabolic-dysfunction-associated steatohepatitis) received 1.8 mg liraglutide once daily via subcutaneous injection or placebo for 12 weeks, with significant improvement in liver biochemistry, including ALT, and markers of inflammation when compared to the placebo group [12]. The gene discussed is GPT; the disease is type 2 diabetes mellitus.